XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | 0.26 | 0.02 | -0.03 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -31.29 | -79.66 | -16.17 | 31.62 |
| Quality | ||||
| ROIC | -8.30% | -10.94% | -18.85% | -6.47% |
| Gross Margin | -14.88% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 766,776.65% | 545,036.18% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.54 | 4.18 | 0.86 | -2.20 |
| Interest Coverage | 22.56 | -8.22 | -32.38 | -10.94 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -22.30 | 77.78 | 0.00 | 0.00 |